top of page


Bukwang registered a composition patent for SOL-804 in the U.S.

approved in the U.S.,Europe, Japan, Eurasia, Australia, and Mexico

Bukwang Pharmaceutical (“Bukwang”) announced that its subsidiary, Dyna Therapeutics (“Dyna”) registered a composition patent for anti-cancer drug ‘SOL-804’ (Title: Solid oral formulation of lipophilic compound) to the U.S. The patent is also approved in Japan, Eurasia, Europe, Australia, Mexico, and Singapore.The process of applying for patents is ongoing in Brazil, Canada, China, Hongkong, Israel, India, Korea, Newzealand, and the republic of South Africa.

Phase 1 clinical study of SOL-804 is going to be conducted soon in Seoul National Univ. hospital with 40 patients after its approval last month. This study will compare SOL-804 to Zytiga in the safety, tolerance, and pharmacodynamics characteristics. It will be randomized, crossed, and single dose administered.

SOL-804 is an improved and proprietary formulated version of a currently available drug for the treatment of metastatic castration-resistant prostate cancer. The global market size of prostate cancer has been getting bigger and passed over 12 trillion dollars in 2019. It will reach 23 trillion dollars in 2027.

Dyna is Bukwang’s 100% owned subsidiary which was established to focus on drug delivery and formulation. Bukwang and Dyna said, “SOL-804 has been registered in the U.S., the biggest market in the world, and expected to decrease food effect in patients with lower doses. With the clinical studies planned, SOL-804 is going to show its outcomes soon.”

|    ​Korean    |
bottom of page